Hyundai Pharm
Seoul, South Korea
NCT Number: NCT04755894
For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.
Looking for future studies?
Notify Me19 year and older
Male
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
☞ BMI (kg/m2) = Weight (kg) / {Long (m)}2
Exclusion criteria
single dose
single dose
Time frame: 0~96 hours
Cmax
Time frame: 0~96 hours
AUC
Hyundai Pharmaceutical Co., LTD.
Industry
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination of HDDO-1756 or Loose Combination of HDDO-17561/HDDO-17562 in Healthy Adult Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial DetailsNCT06461273
Behavior, Body Weight
Newark, New Jersey, United States
View Trial DetailsNCT07578857
Dyslipidemias, Hyperlipidemias
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05643508
Cardiovascular Diseases, Dyslipidemias
Seoul, South Korea
View Trial Details